PUMA BIOTECHNOLOGY INC (PBYI) Stock Fundamental Analysis

NASDAQ:PBYI • US74587V1070

6.82 USD
+0.02 (+0.29%)
At close: Feb 13, 2026
6.86 USD
+0.04 (+0.59%)
After Hours: 2/13/2026, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to PBYI. PBYI was compared to 523 industry peers in the Biotechnology industry. While PBYI belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. PBYI is valued quite cheap, but it does not seem to be growing. These ratings could make PBYI a good candidate for value investing.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • PBYI had positive earnings in the past year.
  • In the past year PBYI had a positive cash flow from operations.
  • In multiple years PBYI reported negative net income over the last 5 years.
  • PBYI had a positive operating cash flow in 4 of the past 5 years.
PBYI Yearly Net Income VS EBIT VS OCF VS FCFPBYI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M

1.2 Ratios

  • PBYI has a better Return On Assets (18.23%) than 96.56% of its industry peers.
  • Looking at the Return On Equity, with a value of 32.08%, PBYI belongs to the top of the industry, outperforming 97.71% of the companies in the same industry.
  • PBYI has a Return On Invested Capital of 22.07%. This is amongst the best in the industry. PBYI outperforms 98.09% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for PBYI is in line with the industry average of 18.27%.
  • The last Return On Invested Capital (22.07%) for PBYI is above the 3 year average (17.97%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 18.23%
ROE 32.08%
ROIC 22.07%
ROA(3y)7.85%
ROA(5y)-2.77%
ROE(3y)24.42%
ROE(5y)N/A
ROIC(3y)17.97%
ROIC(5y)N/A
PBYI Yearly ROA, ROE, ROICPBYI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K

1.3 Margins

  • With an excellent Profit Margin value of 17.44%, PBYI belongs to the best of the industry, outperforming 92.93% of the companies in the same industry.
  • The Operating Margin of PBYI (15.83%) is better than 93.31% of its industry peers.
  • PBYI's Operating Margin has improved in the last couple of years.
  • PBYI has a better Gross Margin (76.91%) than 84.51% of its industry peers.
  • In the last couple of years the Gross Margin of PBYI has declined.
Industry RankSector Rank
OM 15.83%
PM (TTM) 17.44%
GM 76.91%
OM growth 3Y196.89%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.26%
GM growth 5Y-3.58%
PBYI Yearly Profit, Operating, Gross MarginsPBYI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • PBYI has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • Compared to 1 year ago, PBYI has more shares outstanding
  • The number of shares outstanding for PBYI has been increased compared to 5 years ago.
  • The debt/assets ratio for PBYI has been reduced compared to a year ago.
PBYI Yearly Shares OutstandingPBYI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
PBYI Yearly Total Debt VS Total AssetsPBYI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

  • Based on the Altman-Z score of -4.65, we must say that PBYI is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -4.65, PBYI is doing worse than 60.42% of the companies in the same industry.
  • There is no outstanding debt for PBYI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.79
Altman-Z -4.65
ROIC/WACC1.68
WACC13.16%
PBYI Yearly LT Debt VS Equity VS FCFPBYI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M -200M

2.3 Liquidity

  • PBYI has a Current Ratio of 1.74. This is a normal value and indicates that PBYI is financially healthy and should not expect problems in meeting its short term obligations.
  • With a Current ratio value of 1.74, PBYI is not doing good in the industry: 78.20% of the companies in the same industry are doing better.
  • PBYI has a Quick Ratio of 1.62. This is a normal value and indicates that PBYI is financially healthy and should not expect problems in meeting its short term obligations.
  • With a Quick ratio value of 1.62, PBYI is not doing good in the industry: 78.39% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.74
Quick Ratio 1.62
PBYI Yearly Current Assets VS Current LiabilitesPBYI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. Growth

3.1 Past

  • PBYI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 54.17%, which is quite impressive.
  • The Revenue for PBYI has decreased by -12.96% in the past year. This is quite bad
  • The Revenue has been decreasing by -3.28% on average over the past years.
EPS 1Y (TTM)54.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-58.54%
Revenue 1Y (TTM)-12.96%
Revenue growth 3Y-3.09%
Revenue growth 5Y-3.28%
Sales Q2Q%-32.3%

3.2 Future

  • PBYI is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -5.11% yearly.
  • Based on estimates for the next years, PBYI will show a decrease in Revenue. The Revenue will decrease by -0.63% on average per year.
EPS Next Y-8.03%
EPS Next 2Y-18.22%
EPS Next 3Y-3.95%
EPS Next 5Y-5.11%
Revenue Next Year-1.09%
Revenue Next 2Y-0.88%
Revenue Next 3Y-0.74%
Revenue Next 5Y-0.63%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
PBYI Yearly Revenue VS EstimatesPBYI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M 150M 200M 250M
PBYI Yearly EPS VS EstimatesPBYI Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -2 -4 -6 -8

More info and screens

Find the best growth stocksShow best growing peers

7

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 9.22, which indicates a very decent valuation of PBYI.
  • PBYI's Price/Earnings ratio is rather cheap when compared to the industry. PBYI is cheaper than 98.28% of the companies in the same industry.
  • PBYI is valuated cheaply when we compare the Price/Earnings ratio to 27.97, which is the current average of the S&P500 Index.
  • PBYI is valuated correctly with a Price/Forward Earnings ratio of 16.72.
  • 95.22% of the companies in the same industry are more expensive than PBYI, based on the Price/Forward Earnings ratio.
  • PBYI's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.96.
Industry RankSector Rank
PE 9.22
Fwd PE 16.72
PBYI Price Earnings VS Forward Price EarningsPBYI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, PBYI is valued cheaper than 98.85% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, PBYI is valued cheaper than 99.43% of the companies in the same industry.
Industry RankSector Rank
P/FCF 8.02
EV/EBITDA 5.4
PBYI Per share dataPBYI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 1 2 3 4

4.3 Compensation for Growth

  • The decent profitability rating of PBYI may justify a higher PE ratio.
  • PBYI's earnings are expected to decrease with -3.95% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-18.22%
EPS Next 3Y-3.95%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for PBYI!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PUMA BIOTECHNOLOGY INC

NASDAQ:PBYI (2/13/2026, 8:00:02 PM)

After market: 6.86 +0.04 (+0.59%)

6.82

+0.02 (+0.29%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06
Earnings (Next)02-26
Inst Owners71.41%
Inst Owner Change-0.77%
Ins Owners15.12%
Ins Owner Change-0.47%
Market Cap343.66M
Revenue(TTM)212.00M
Net Income(TTM)36.98M
Analysts42.86
Price Target5.1 (-25.22%)
Short Float %8.41%
Short Ratio9.12
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)142.48%
Min EPS beat(2)14.59%
Max EPS beat(2)270.37%
EPS beat(4)4
Avg EPS beat(4)237.87%
Min EPS beat(4)14.59%
Max EPS beat(4)394.12%
EPS beat(8)7
Avg EPS beat(8)129.74%
EPS beat(12)10
Avg EPS beat(12)120.97%
EPS beat(16)14
Avg EPS beat(16)232.31%
Revenue beat(2)2
Avg Revenue beat(2)3%
Min Revenue beat(2)1.23%
Max Revenue beat(2)4.77%
Revenue beat(4)4
Avg Revenue beat(4)4.4%
Min Revenue beat(4)1.23%
Max Revenue beat(4)10.36%
Revenue beat(8)7
Avg Revenue beat(8)4.18%
Revenue beat(12)10
Avg Revenue beat(12)4.08%
Revenue beat(16)13
Avg Revenue beat(16)5.33%
PT rev (1m)7.14%
PT rev (3m)15.39%
EPS NQ rev (1m)-1.3%
EPS NQ rev (3m)-9.95%
EPS NY rev (1m)0.36%
EPS NY rev (3m)11.22%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)-0.11%
Revenue NY rev (3m)2.31%
Valuation
Industry RankSector Rank
PE 9.22
Fwd PE 16.72
P/S 1.62
P/FCF 8.02
P/OCF 7.99
P/B 2.98
P/tB 4.81
EV/EBITDA 5.4
EPS(TTM)0.74
EY10.85%
EPS(NY)0.41
Fwd EY5.98%
FCF(TTM)0.85
FCFY12.47%
OCF(TTM)0.85
OCFY12.51%
SpS4.21
BVpS2.29
TBVpS1.42
PEG (NY)N/A
PEG (5Y)N/A
Graham Number6.17
Profitability
Industry RankSector Rank
ROA 18.23%
ROE 32.08%
ROCE 27.93%
ROIC 22.07%
ROICexc 102.97%
ROICexgc N/A
OM 15.83%
PM (TTM) 17.44%
GM 76.91%
FCFM 20.22%
ROA(3y)7.85%
ROA(5y)-2.77%
ROE(3y)24.42%
ROE(5y)N/A
ROIC(3y)17.97%
ROIC(5y)N/A
ROICexc(3y)84.91%
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)22.75%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y271.17%
ROICexc growth 5YN/A
OM growth 3Y196.89%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.26%
GM growth 5Y-3.58%
F-Score7
Asset Turnover1.05
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.79
Debt/EBITDA 0
Cap/Depr 1.11%
Cap/Sales 0.06%
Interest Coverage 4.71
Cash Conversion 96.22%
Profit Quality 115.93%
Current Ratio 1.74
Quick Ratio 1.62
Altman-Z -4.65
F-Score7
WACC13.16%
ROIC/WACC1.68
Cap/Depr(3y)62.9%
Cap/Depr(5y)77.72%
Cap/Sales(3y)2.82%
Cap/Sales(5y)3.47%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)54.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-58.54%
EPS Next Y-8.03%
EPS Next 2Y-18.22%
EPS Next 3Y-3.95%
EPS Next 5Y-5.11%
Revenue 1Y (TTM)-12.96%
Revenue growth 3Y-3.09%
Revenue growth 5Y-3.28%
Sales Q2Q%-32.3%
Revenue Next Year-1.09%
Revenue Next 2Y-0.88%
Revenue Next 3Y-0.74%
Revenue Next 5Y-0.63%
EBIT growth 1Y3.58%
EBIT growth 3Y187.73%
EBIT growth 5YN/A
EBIT Next Year93.13%
EBIT Next 3Y23.6%
EBIT Next 5YN/A
FCF growth 1Y825.85%
FCF growth 3Y23.46%
FCF growth 5Y11.98%
OCF growth 1Y77.42%
OCF growth 3Y23.52%
OCF growth 5Y11.7%

PUMA BIOTECHNOLOGY INC / PBYI FAQ

Can you provide the ChartMill fundamental rating for PUMA BIOTECHNOLOGY INC?

ChartMill assigns a fundamental rating of 5 / 10 to PBYI.


What is the valuation status of PUMA BIOTECHNOLOGY INC (PBYI) stock?

ChartMill assigns a valuation rating of 7 / 10 to PUMA BIOTECHNOLOGY INC (PBYI). This can be considered as Undervalued.


What is the profitability of PBYI stock?

PUMA BIOTECHNOLOGY INC (PBYI) has a profitability rating of 7 / 10.


Can you provide the financial health for PBYI stock?

The financial health rating of PUMA BIOTECHNOLOGY INC (PBYI) is 5 / 10.